Edwards Lifesciences [NYSE:EW]
Designing Heart Valves for the Years Ahead

A surgeon can assess whether a replacement heart valve is functioning before the patient leaves the operating room. What cannot be established that day is how its tissue will respond to years of repeated opening and closing, or what treatment options may remain if another intervention becomes necessary.

These questions influence more than the selection of a replacement valve. They shape decisions about tissue durability, device design and how patients may be treated as their needs change over time.

Edwards Lifesciences [NYSE:EW] approaches structural heart innovation with that longer perspective. Its RESILIA tissue technology addresses a major cause of biological valve deterioration, while its surgical valve platforms incorporate features developed for specific anatomical and procedural requirements. Clinical studies then examine how these technologies perform over time. Its INSPIRIS RESILIA aortic valve and MITRIS RESILIA mitral valve demonstrate how advances in tissue preservation can be translated into devices designed for different positions within the heart.

Protecting the Tissue Before Implantation

Biological heart valves must retain their flexibility and function under continuous mechanical stress. One challenge is calcification, which can progressively stiffen the valve tissue and contribute to structural deterioration of the valve.

Edwards addresses this at the material level through RESILIA tissue, developed from bovine pericardium using its proprietary Integrity Preservation technology. The preservation process incorporates stable-capping, which blocks residual aldehyde groups associated with calcium binding. A second process, glycerolization, mitigates residual glutaraldehyde and enables the tissue to be stored dry rather than maintained in a liquid preservative. These processes address different needs. The calcium-blocking treatment is intended to improve resistance to tissue calcification, while dry storage simplifies aspects of valve handling and preparation.

The technology emerged from an extensive development program involving laboratory evaluation and preclinical investigation. In a juvenile sheep model, RESILIA-treated tissue demonstrated 72 percent less calcium content than the comparison tissue after eight months. That result established evidence of improved resistance to calcification in the experimental setting. Clinical follow-up is necessary to determine how the material performs in implanted human valves over longer periods.

Edwards Lifesciences connects tissue preservation with specialized valve design, developing structural heart technologies that address immediate procedural requirements while considering future treatment needs.

Edwards has carried this tissue platform into surgical valve designs, allowing the material innovation to support different treatment applications.

Planning Beyond the First Aortic Procedure

The INSPIRIS RESILIA aortic valve brings the tissue technology into a surgical platform built on Edwards’ established PERIMOUNT and Magna Ease designs. Beyond its RESILIA-treated leaflets, the valve incorporates features intended to facilitate surgical implantation and accommodate future treatment needs. Its VFit technology is the part aimed at a later procedure. The design includes an expansion zone intended to permit controlled enlargement if a subsequent transcatheter valve-in-valve procedure is considered.

That possibility can matter when a patient undergoes surgical replacement earlier in life. The initial valve’s dimensions and construction may affect the feasibility of treatment years later, when the patient’s clinical circumstances could be very different. Edwards developed VFit with this possibility in mind, but its expansion characteristics rest on bench testing. Clinical studies have not established the safety and effectiveness of the relevant INSPIRIS model for valve-in-valve use.

The distinction is important. The technology represents an effort to anticipate future interventions, not a guarantee that any particular patient will be eligible for them. It nevertheless illustrates how Edwards considers the relationship between the first procedure and potential subsequent care during device development.

Engineering for the Mitral Position

The anatomical and mechanical demands of the mitral position differ from those of the aortic valve. Edwards addresses these requirements through MITRIS RESILIA, a surgical mitral valve that incorporates the same underlying tissue-preservation technology. MITRIS is built on the Carpentier-Edwards PERIMOUNT platform but features a design specific to mitral replacement. Its saddle-shaped sewing cuff is intended to resemble the native mitral annulus. At the same time, low-profile stents are designed to limit protrusion into the left ventricle and avoid interference with blood flow through the left ventricular outflow tract.


These details reflect the importance of how a replacement device fits and functions within the surrounding anatomy. The valve also incorporates cobalt-chromium bands that remain visible under fluoroscopy. They can help clinicians identify the valve’s position and potential landing zone when evaluating future transcatheter intervention. As with INSPIRIS, such design features support planning rather than establishing the safety or suitability of a later procedure. MITRIS also benefits from RESILIA tissue’s dry-storage properties. Eliminating the customary rinsing step associated with certain preserved tissue valves simplifies preparation in the operating room.

The result is an example of Edwards applying a common tissue technology while engineering the rest of the device around the requirements of a different valve position.

Measuring Performance Across a Decade

Long-term clinical evidence gives Edwards’ tissue development a more substantial foundation than laboratory performance alone.

In May 2026, the company announced the 10-year findings from the COMMENCE aortic trial, presented at the American Association for Thoracic Surgery Annual Meeting. The prospective, multicenter study investigated a surgical bioprosthetic aortic valve incorporating RESILIA tissue. At 10 years, the reported results showed 97.9 percent freedom from structural valve deterioration and 97.8 percent freedom from reoperation due to structural valve deterioration.

The study also reported sustained hemodynamic performance, including stable pressure gradients and effective valve-opening area over time. Across participating centers in the United States and Europe, 192 patients completed the 10-year follow-up visits. These findings are significant because they connect the original tissue-preservation approach with observed performance over an extended period. They provide clinicians with information relevant to assessing the technology’s durability rather than relying solely on anticipated material benefits.

The evidence also has defined limits. COMMENCE is a nonrandomized, single-arm study, and its reported outcomes cannot establish how long an individual patient’s valve will function. Nor do the findings independently establish equivalent long-term performance for every device incorporating RESILIA tissue.

For Edwards, the importance of the research lies in continuing to evaluate implanted technologies as patients progress through their lives. The scale of clinical use has also grown. By
May 2026, Edwards reported that more than 500,000 patients worldwide had received its surgical or transcatheter technologies incorporating RESILIA tissue.

Connecting Innovation Across Structural Heart Care

Edwards’ work extends beyond the surgical applications of RESILIA.

Its broader structural heart portfolio includes the SAPIEN family of transcatheter aortic valves, which provides a catheter-based approach to aortic valve replacement in appropriately selected patients. The SAPIEN 3 Ultra RESILIA system also brings RESILIA tissue into a transcatheter platform.

Other technologies address structural heart conditions involving the mitral and tricuspid valves, expanding the procedural approaches available to specialist Heart Teams in markets where the respective devices are authorized. This breadth matters because structural heart disease does not follow one treatment pathway. The appropriate intervention depends on the affected valve, patient anatomy and clinical circumstances. Age and potential future treatment needs can also influence the discussion.

Edwards’ approach combines specialized devices with ongoing clinical investigation, allowing its development programs to address both immediate procedural needs and the long-term performance of treatments. The company’s surgical portfolio illustrates this relationship particularly clearly. RESILIA begins with changes to tissue preservation, while INSPIRIS and MITRIS incorporate that material into devices designed for different anatomical requirements.

The COMMENCE findings bring another dimension to the process by examining how the tissue technology performs after implantation in the aortic position. A heart valve replacement is performed on a particular day, but its implications extend well beyond the operation. Tissue durability, valve design and the evidence available to clinicians can influence decisions throughout the patient’s subsequent care.

Edwards Lifesciences continues to develop its technologies around that longer treatment journey, connecting the engineering of today’s replacement valves with the clinical questions that may arise years later.